Search

everythinglearnresearchcommunity

for

Search:↓

Blocking α-toxin helps heal Staphylococcus aureus-infected wounds faster in both normal and diabetic mice, with different effects on their immune responses.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Basal cell epithelioma-like changes are most similar to normal basal cells.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Merkel cell increase is specific to certain skin diseases, not general skin growth.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Ocrelizumab may cause pancreatitis in some patients.

Sciellin is a protein that helps form protective layers in skin, hair, and nails.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

Plet-1 protein helps hair follicle cells move and stick to tissues.

Ustekinumab treatment didn't prevent frontal fibrosing alopecia.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Ocrelizumab may cause total body hair loss in some patients.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

A new one-step test can quickly identify skin cancer during surgery.

Dupilumab effectively treated severe alopecia areata in a child.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

The upper dermal sheath can regenerate hair in rats.